Pulnovo Medical, a China-based medtech company developing treatments for pulmonary hypertension and heart failure, has raised $100 million in an oversubscribed round led by Medtronic, the world’s largest medtech company.
Global pharmaceutical company AstraZeneca is set to make a $15 billion investment in China through 2030 to expand its manufacturing and research and development capabilities in the country.
Bupa Hong Kong, the Chinese division of multinational health insurer and provider Bupa, is massively expanding its coverage in mainland China, with a new scheme covering 3,600 hospitals across the country. The company is simultaneously expanding coverage to 3,000 ‘service points’ on the island of Hong Kong.
Maximilian Peschel has been based in China since April 2025, working for Chinese healthcare investment firm Silver Mountain Group and German hospital group Artemed SE on a hospital privatisation project in Chongqing. In an interview with HBI, he discussed the project, and the challenges and opportunities for foreign investors looking to enter China’s hospital sector.
China has responded tit-for-tat against the EU’s decision to ban China from selling medical devices to EU governments, barring EU medical device producers from selling to Chinese government hospitals.
China’s expanding digital health sector, driven by advances in AI technology and rising consumer demand for virtual medical services, presents growing opportunities for European investors seeking to enter the market.
We’re about to release a Special Report on healthcare investment in Asia. The report offers a comprehensive overview of the dynamics, trends and opportunities in the healthcare markets of eight hugely important countries in the region: China, India, South Korea, Thailand, Vietnam, Indonesia, Malaysia and the Philippines.
Private equity firms CVC Capital Partners, KKR, and Macquarie, have been shortlisted to compete for a minority stake of Luz Saúde, one of Portugal’s largest private healthcare groups. Fidelidade reportedly intends to sell between 30% and 49% of Luz Saúde, with the receipt of binding offers expected in July, and the deal to close before […]
The EU Commission is banning EU member state governments from purchasing medical devices from Chinese companies. The ban applies to all public procurement contracts worth more than €5 million, but does not apply to private hospitals.
The Hong Kong division of multinational private health insurer and provider Bupa is expanding its direct settlement scheme into mainland China by partnering with four Chinese private hospital groups that operate in the Guangdong–Hong Kong–Macao Greater Bay Area. The move comes after Bupa Group withdrew from the country in 2023, and after the Chinese government decided to open up certain regions to foreign healthcare investment in 2024.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.